Work

Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry

Year: 2026

Type: article

Abstract: AIMS: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is widely used as an enrichment criterion in heart failure (HF) randomized controlled trials (RCTs), yet cut-offs vary. This study aims to provide evidence-based guidance on selecting NT-proBNP cut-offs to optimize the balance between event enrichment and screening failure across HF subgroups. METHODS: Using the Swedish HF Registry (SwedeHF), we applied NT-proBNP cut-offs from prior RCTs (200-5000 pg/mL) and calculated 1-year incidence proportions of a composite CV outcome (CV death or first HF hospitalisation) across subgroups by ejection fraction (EF), care setting (inpatient/outpatient), atrial fibrillation (AF), chronic kidney disease (CKD), and obesity. We quantified point and relative increases in event proportions and potential screening failure at each cut-off and identified optimal prognostic thresholds by maximizing Youden's index. RESULTS: Among 43,750 HF patients, median NT-proBNP was lower in HFpEF/HFmrEF vs HFrEF, outpatients vs inpatients, sinus rhythm vs AF, obese vs not obese, and patients without CKD vs with CKD (all p < 0.001). Higher NT-proBNP cut-offs increased 1-year composite CV proportions but excluded more patients. For example, In HFrEF outpatients, the 1-year proportion rose from 22.0% (no cut-off) to 24.3% at ≥600 pg/mL and 26.2% at ≥1,200 pg/mL, a 19% (95% CI:14.0-24.4) relative increase. Screening failure rose from 16.0% to 26.4% at these respective cut-offs. Optimal prognostic thresholds aligned with or exceeded subgroup median NT-proBNP values. CONCLUSION: Higher NT-proBNP cut-offs were associated with increased event enrichment but also higher screening failure. These findings support the use of higher cut-offs currently used in HF RCTs and suggest that future trials should tailor NT-proBNP cut-offs to trial aims, balancing enrichment with enrolment feasibility and considering obesity and CKD in addition to EF and AF.

Source: ESC Heart Failure

DOI: 10.1093/eschf/xvag089